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Abstract: Purpose Total pancreatectomy may improve symptoms in patients with severe end-
stage chronic pancreatitis. This might be achieved whilst preserving both the
duodenum and spleen (DPSPTP). Mature clinical outcomes of this approach are
presented. Methods Single centre prospective cohort study performed between
September 1996 and May 2016. Demographic, clinical details, pain scores and
employment status were prospectively recorded during clinic attendance. Results 51
patients (33 men, 18 women) with a median (interquartile range) age of 40.8 (35.3-
49.4) years, a median weight of 69.8 (61.0-81.5) Kg, and a median body mass index of
23.8 (21.5-27.8), underwent intended duodenum-and spleen-preserving near-total
pancreatectomy for end-stage chronic pancreatitis. Aetiology was excess alcohol in 25,
idiopathic (no mutation) in 15, idiopathic (SPINK-1/CFTR mutations) in two, hereditary
(PRSS1 mutation) in seven, and one each post-necrotising pancreatitis and obstructive
pancreatic duct divisum in 1. The main indication for surgery was severe pain. Findings
included parenchymal calcification in 79% and ductal calculi in 24%, a dilated main
pancreatic duct in 57% and a dilated main bile duct in 17%, major vascular
involvement in 27%, and pancreato-peritoneal fistula in 2%. Post-operative
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complications occurred in 16 patients with one death. Median pain scores were 8 (7-8)
preoperatively and 3 (0.25-5.75) at 5 years (p=0.013). Opiate analgesic use was
significantly reduced post-operatively (p=0.048). Following surgery 22 (63%) of 38
patients of working age re-entered employment compared with 12 (33%) working pre-
operatively (p=0.016). Conclusion Duodenum-and spleen-preserving near-total
pancreatectomy provided long-term relief in adult patients with intractable chronic
pancreatitis pain, with improved employment prospects.
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Response to reviewers 
 
Re: Duodenum and spleen preserving near-total pancreatectomy can provide long-term 
pain relief in patients with end-stage chronic pancreatitis 
 
Authors: A.R.G. Sheel, R.D. Baron , L.D. Dickerson , P. Ghaneh, F. Campbell, M.G.T. Raraty, 
V. Yip, C.M. Halloran , J.P. Neoptolemos. 
 
 
Thank you for all the helpful comments from the reviewers. 
 




“The table III could be presented in a more clearly manner”. 
 
This has been made modified accordingly. 
 
“also figure 5 could be improved in scaling.” 
 
This has been made modified accordingly. 
 
“Figure 5 – meaning 4 - is showing that there is an increase of intake of strong opiates at the 
follow up time of five yaers, it could be interesting to find out the reason for this trend.    
 
We have inserted in the Discussion: 
 
“The longer-term oral morphine equivalent intake remained significantly lower after 
duodenum preserving total pancreatectomy (with or without spleen preservation), although 
from year to year there was a variance of opiate intake, reflecting the complex 
pathophysiological mechanisms of pain in CP [12]. “ 
 
There are already topic-related reviews published, e.g. Bellon et al. showed in 2019 that there 
is a high rate of patients who continued consuming alcohol (37.9%) after undergoing 
duodenum-preserving pancreatic head resection because of chronic pancreatitis. 
 
We are aware of the excellent studies on from Hamburg, but the study by E Bellon et al in 2019 




authors' response to reviewers' comments Click here to access/download;authors' response to reviewers'
comments;Response to reviewers.docx
1. The authors already reported their experience with DPSPTP in the Br J Surg in 2003. 
These patients are included in the current series. The authors need to state more clearly what 
is the exact overlap of patients and what is the additional value of the current series other than 
its larger size. 
 
This is now explained in the Methods:  
 
“There were 19 patients between September 1996 and November 2002 (none in December) 
and a further 32 patients from January 2003 and May 2016. All patients with continued follow-
up were included in this series.” 
 
 
2. While the authors previously removed all pancreatic parenchyma (this is TP) along the 
duodenum they modified their technique to a subtotal head resection after 2003. Subtotal is not 
total and, therefore, the term DPSPTP is misleading. 
 
In the Title, Abstract and the whole of the Manuscript we refer to the procedures as: 
 
“Duodenum and spleen preserving near-total pancreatectomy” 
 
 
3. The authors report on 7 patients with hereditary pancreatitis. These patients are at 
increased risk for pancreatic cancer. In these patients TP is adequate, but I am not sure if leaving 
behind pancreatic tissue prone to cancer is adequate. How many of these patients received a 
subtotal head resection, why, and how long was the follow up in these patients. 
 
We have provide further clarification in the Results: 
 
“Five patients with Hereditary Pancreatitis (PRSS1 mutation) had a duodenum and spleen 
preserving total pancreatectomy before 2003 and two had a duodenum and spleen preserving 
near-total pancreatectomy from 2003, none of whom developed pancreatic cancer. Two 
additional patients with a PRSS1 mutation underwent DPSPTP without clinical evidence of 
CP as part of a pancreatic cancer screening program and are not included in this series, although 
both had good post-operative long-term outcomes.” 
 
4. Of 51 patients with DPSPTP an unknown (but probably large) number of patients 
received a subtotal pancreatectomy along the duodenum, n=8 received splenectomy for 
technical and other reasons and n=2 received a radical TP with duodenectomy for neoplasia. 
How many patients indeed received a DPSPTP?? 
 
This is already clear from the aforementioned: 49 had a duodenum preserving near total or total 
pancreatectomy with or without spleen preservation – DP(SP)TP – and two had radical total 
pancreatectomy for neoplasia. 
 
This is not a RCT comparing two interventions where an ITT analysis is crucial. If the authors 
intend to report outcomes for a specific procedure, they only should include patients who in 
fact did receive this specific procedure. 
 
We agree that this is not an RCT. But the approach we have taken is to report all of the data as 
would take place in clinical practice (so called “real-world reporting) to avoid any bias in 




1. Methods section: please explain better that bile duct is marsupialized (I understand but could 
be improved)  
 
In the operative procedure we have now added: 
 
“The bile duct is marsupialized within the bed of the pancreatic head by opening this 
longitudinally and then inserting six or more interrupted 4/0 sutures to approximate the edges 
of the cut bile duct to the adjacent tissues.” 
 
2. Operative outcomes: one patient had a pancreatic head resection. Coul you explain the reason 
to resect the rim of pancres left? 
 
This is now better explained: 
 
“resection of a large uncinate process remnant which had been incompletely removed at the 
first operation (1)” 
 
3. Patient outcomes: How many moved to open access appointments and how many lost to 
follow up? 
 
This has now been modified to: 
 
“17 patients were lost to follow-up and 12 were discharged”. 
 
In the Discussion we have added: 
 
“Compliance with long-term follow up is often a problem with this group of patients and must 
be regarded as a limitation in this as well as other studies. Nevertheless, there were 22 (57.9%) 
of 38 patients of working age who were able to return to gainful work, compared to 28.1% in 
the one only previously reported series of total radical pancreatectomy (with duodenectomy 
and splenectomy) for chronic pancreatitis [28]. “ 
 
 
4. Part of the procedure is like a Warshaw technique. Left portal hypertension had been 
frequently described in such cases. Did you daignose any case of left portal hypertension? If 
not wgy did you think that occur? 
 
This might have occurred acutely during surgery and therefor a splenectomy was carried out. 
 
Radiologically on CT we had a minor case of selenic infraction (Table III). 
 
Otherwise we simply did not have this as a clinical problem. We have already stated in the 
Results that “No patients returned to theatre for splenic complications.”. 
 
Also we never had had nay cases of variceal bleeding. 
 
 
5. Table 1 Bbody is Body 
 
This has been corrected. 
 
6. Table 6 Delayed gastric emptynig has been considered Clavien I and II Why? nasogastric 
tube vs waiting? Main problem with surgicl site infection (scar? or intraabdominal abscess? 
 
Thank you – this has been adjusted. 
 
Comment perhaps in title could be included Liverpool procedure if you like. 
 
We have changed this to: 
 
“The Liverpool duodenum and spleen preserving near-total pancreatectomy can provide long-
term pain relief in patients with end-stage chronic pancreatitis”. 
 
Reviewer #4:  
 
Major: 
1. The indication for this type of procedure has to be more specific. In the methods section 
is stated that it is indicated for a subset of patients with end-stage disease affecting the entire 
pancreas. What is exactly meant by affecting entire pancreas? Calcifications? Inflammation? 
 
Indication is a big problem with these types of surgery (TP / TP-IAT). In international literature, 
it is still unclear in which patients we have to perform these procedures. Maybe the authors can 
shed more light and make recommendations for indication in the discussion section. 
 
We have added the word ‘debilitating” to give the following definition: 
 
“This operation is only offered to the subset of patients with debilitating end-stage disease 
affecting the entire pancreas with chronic severe abdominal pain unresponsive to optimal 
medical management. Patients having previously undergone partial pancreatectomy with on-
going or recurrent symptoms due to progressive disease in the remnant pancreas are also 
considered. Patients without diabetes mellitus meeting the above criteria are considered after 
counselling regarding postoperative diabetes management and complications. All patients must 
demonstrate abstinence from alcohol for more than six months. The procedure is 
contraindicated if malignancy is suspected, but the presence of porto-mesenteric venous 
thrombosis with varices is only a relative contraindication.” 
 
This represents 51 of 778 patients with confirmed CP 0r 6.6%. 
 
Examples are given in Figure 2: 
 
Figure 2a and b. Female with idiopathic (CFTR mutation) chronic pancreatitis. Extensive 
parenchymal and ductal calcification is seen throughout the pancreas with significant upstream 
main pancreatic duct dilatation and parenchymal atrophy. Figure 2c. Female with PRSS1 N29I 
mutation (hereditary pancreatitis). Calcification within the pancreatic head and upstream and 
main pancreatic duct dilatation. Significant disease progression over 12 months with large 
volume abdomino-pelvic pancreatic ascites from a pancreato-peritoneal fistula and new gastric 
and splenic venous collateralisation. 
 
So in one case complete calcification, and in the other only calcification in the head of pancreas 
but with pancreatic ascites from a pancreato-peritoneal fistula and gastric and splenic venous 
collateralization from vascular involvement. 
 
Both diabetics with exocrine failure. 
 
The question of TPIAT is only relevant for mainly hereditary recurrent acute pancreatitis in 
children and young adults with preserved exocrine and endocrine function. 
 
We have now inserted a paragraph in the Discussion (see below). 
 
2. There is little information about the insulin dependent diabetes after the surgery. It is 
known that patients can develop a so-called 'brittle' diabetes after TP, and this is very difficult 
to control. This is one of the reasons why the islet auto transplantation technique is developed. 
Please provide more information about the diabetes in these patients (units of insulin, number 
of hyper/hypoglycemia if possible). 
 
Thirty-three patients (65%) were diabetic, 31 (61%) insulin dependent and two (4%) controlled 
with oral anti-hypoglycaemics before surgery. 
 
All required insulin after surgery and were managed by the specialized diabetic service using 
the latest techniques as they evolved. We do not have any specific information other than there 
were few problems. 
 
3. The data of pain scores and opioid use during follow-up are based on low numbers of 
patients (pain score: between 8 and 21 patients; opioids between 7 and 25 patients). This is 
however a well-known and insurmountable problem in long-term outcome studies. But please 
report this as limitation in the discussion. 
 
Yes – thank you, we have modified the Discussion: 
 
“Compliance with long-term follow up is often a problem with this group of patients and must 
be regarded as a limitation in this as well as other studies. Nevertheless, there were 22 (57.9%) 
of 38 patients of working age who were able to return to gainful work, compared to 28.1% in 
the one only previously reported series of total radical pancreatectomy (with duodenectomy 
and splenectomy) for chronic pancreatitis [28]. “ 
 
Minor: 
1. Please use the STROBE reporting checklist. Some details are missing in the current 
manuscript  
 
I appreciate the Reviewers intention, but this is a prospective study over 20 years. Application 
of STROBE is not strictly applicable – for example, it was impossible to ascertain 20 years ago 
what the sample size would be and what the primary hypothesis would be. 
 
Many of the modern requirements are around statistics and statistical modelling. If we did all 
of these the paper would be unintelligible for what is - at the end of the day a specialist surgical 
topic in sample size of only 51 patients. 
 
I have however been through the checklist – we have mentioned potential limitations however 
such as the difficulty in follow-up. 
 
I think we have all of the ley points covered. 
 
2. Introduction, p2: The incidence rates are reported as numbers per 10^5. I would prefer 
to use 100.000 instead of 10^5. 
 
I am used to using 10^5. 
 
3. Results: Previous medication use and previous surgery is reported in the results section. 
But I am missing the proportion of patients that had previous endoscopy. 
 
We do not used endoscopy to treat patients with advanced CP. 
 
4. Results, p4: in one patient the predominant symptom was not pain. For which reason 
this patient underwent surgery? 
 
In the Results we have added: 
 
“This patient had CP associated with Hereditary Pancreatitis (with a PRSS1) along with 
parenchymal calcification and both endocrine and exocrine failure, who requested a DPSPTP 
in his sixth decade of life mainly as a prophylactic measure against pancreatic cancer.” 
 
 
5. Page 5: Punctuation is missing last sentence of the first paragraph "patient outcomes" 
 
6. Discussion: TP-IAT is not mentioned in the manuscript. Please discuss TP-IAT in the 
discussion. It is nowadays a very important procedure in patients with end-stage CP. 
 
As mentioned above, by definition patients with end stage CP have very few islets and so 
cannot have TP-IAT. 
 
The indication for TP-IAT is mainly hereditary recurrent acute pancreatitis in children and 
young adults with preserved exocrine and endocrine function. 
 
We have now inserted a paragraph in the Discussion (see below). 
 
7. Table 1: It will be more clear when the authors divide risk factors in "etiology" and 
"current preoperative risk factors (alcohol use and smoking preoperatively)". 
 
I am not sure that I understand this point – we are referring to etiological risk factors. 
 
8. Table 1: Body mass index is written with two b's. 
 
Thank you – corrected. 
 
9. Table 4: Title suggests that these are all existing studies about TP(IAT). I think that the 
authors mean that these are all studies about organ-preserving TP? There are many more 
articles about TP-IAT without saving the duodenum and spleen. 
 




Under the last section of introduction:  
 TPIAT should be mentioned here (see Bellin MD, et al. No islets left behind: islet 
autotransplantation for surgery-induced diabetes., Bellin MD, et al. How Durable Is 
Total Pancreatectomy and Intraportal Islet Cell Transplantation for Treatment of 
Chronic Pancreatitis? Chinnakotla S, et al. Factors Predicting Outcomes After a Total 
Pancreatectomy and Islet Autotransplantation Lessons Learned From Over 500 Cases, 
Walsh RM, et al. Improved quality of life following total pancreatectomy and auto-islet 
transplantation for chronic pancreatitis, and Wilson GC, et al. Long-term outcomes 
after total pancreatectomy and islet cell autotransplantation: is it a durable operation?)  
 TPIAT also improves survival over TP alone (see Garcea G, et al. Patient satisfaction 
and cost-effectiveness following total pancreatectomy with islet cell transplantation for 
chronic pancreatitis.). 
 TPIAT is a better option for children with hereditary forms of pancreatitis than TP-
alone, given the excellent metabolic outcomes in younger patients (see Bellin MD, et 
al. Total Pancreatectomy With Islet Autotransplantation Resolves Pain in Young 
Children With Severe Chronic Pancreatitis, Bellin MD, et al. Quality of life improves 
for pediatric patients after total pancreatectomy and islet autotransplant for chronic 
pancreatitis, and Chinnakotla S, et al. Total pancreatectomy and islet 
autotransplantation in children for chronic pancreatitis: indication, surgical techniques, 
postoperative management, and long-term outcomes.). 
 
Under study design: This study is more appropriately classified as a retrospective review of 
prospectively collected data (case series).  
 
No – this was a prospective study. 
 
Under indications for DPSPTP: TPIAT is a well-established, extensively studied treatment of 
chronic pancreatitis for relief of pain with mitigation of postoperative diabetes. Were these 
patients considered for TPIAT prior to DPSPTP (in which case this would be considered a 
salvage or palliative procedure compared with TPIAT)? If not, what were the reasons for 




Under indications for DPSPTP: It is noted by the authors that, “Patients without diabetes 
mellitus meeting the above criteria are considered after counselling regarding postoperative 
diabetes management and complications.” Table 1 indicates that 65% of the patients treated 
had pre-operative diabetes as a symptom, please explain more regarding the indication for 
surgery in the setting of pre-operative diabetes versus no pre-operative diabetes, and were 
patients counselled that their risk of post-operative diabetes might be less if they underwent 
concurrent islet autotransplantation. 
 
The indications are clearly described. 
 
This operation is only offered to the subset of patients with debilitating end-stage disease 
affecting the entire pancreas with chronic severe abdominal pain unresponsive to optimal 
medical management. Patients having previously undergone partial pancreatectomy with on-
going or recurrent symptoms due to progressive disease in the remnant pancreas are also 
considered. Patients without diabetes mellitus meeting the above criteria are considered after 
counselling regarding postoperative diabetes management and complications. All patients must 
demonstrate abstinence from alcohol for more than six months. The procedure is 
contraindicated if malignancy is suspected, but the presence of porto-mesenteric venous 
thrombosis with varices is only a relative contraindication.  
 
Under data collection: A series like this should include diabetes outcomes, especially if the 
procedure is considered an alternative to TPIAT. Considering that TPIAT has such extensive 
documentation of diabetes outcomes (see above suggested references). In order to compare this 
procedure with other standard surgical treatments of pancreatitis, data on diabetes outcomes is 
essential. Again, if this procedure is being presented as a salvage or palliative therapy, this 
should be made explicit. 
 
Under patient outcomes: Can the authors comment on the one-year post-operative daily doses 
of short- and long-acting insulin in the cohort, and the range of A1c. 
 
Follow-up and management of diabetes mellitus was undertaken in the specialist diabetic clinic. 
We did not have all of this information for the duration of the 20-year study. 
 
Under patient outcomes, second paragraph: What is the time to determining "complete 
recovery," as in, how long were patients followed before being "discharged from clinical 
follow-up"? 
 
Complete recovery meaning they were completely stable requiring no variation in their 
management, other than monitoring of their diabetes mellitus. 
 
Follow-up is clearly described in the Methods. 
 
 
Under discussion, first paragraph: Table IV does not include TPIAT series, however if these 
patients were not first considered for TPIAT, the complication and mortality data for TPIAT 
should be presented for comparison. Clinicians trying to decide whether to refer a patient for 
TPIAT versus DPSPTP should be aware of these comparisons. Otherwise, if the patients in this 
series were considered not to be candidates for TPIAT, it should be made explicit throughout 
the article that this procedure is a salvage therapy when TPIAT is no longer an option. 
 
Under discussion, second paragraph: Again, TPIAT is not referenced in comparison to this 
series, so the authors cannot claim that their operation “compares favorably… in terms of post-
operative results and, unlike almost all these studies, we report sustained long-term benefits.” 
 
Under conclusion: This is only a meaningful conclusion if the patients were considered not to 
be candidates for TPIAT. 100% of this cohort had insulin-dependent diabetes after the 
procedure, whereas 30-40% of TPIAT patients end up insulin independent at one year, and 
those who remain on insulin are frequently maintained on one injection of long-acting insulin 
daily. For the DPSPTP to be accepted as an alternative to TPIAT, the authors need to report 
more detailed metabolic outcomes and compare outcomes with TPIAT, which is already an 
established and increasingly used surgical treatment of chronic and recurrent acute pancreatitis. 
If it is to be accepted as a salvage or palliative procedure when TPIAT is not an option, then I 
again suggest that the authors make this distinction explicit throughout the manuscript, and in 
the conclusion. 
 
Yes but only 7% are insulin-dependent diabetics in the first palce. 
 
The role of TP-IAT is mainly hereditary recurrent acute pancreatitis in children and young 
adults with preserved exocrine and endocrine function. 
 
For adults it is highly controversial, where its use has been in those with so called ‘early CP”, 
but the latest International Guidelines show that “early CP” cannot be diagnosed. 
 
The studies by Bellin and Chinnakotla are the same series of patients. 
 
In the latest study, Melena Bellin and her colleagues reported on 215 patients with following 
inmportant points: (a) they did not define CP or how it was diagnosed – an extrmely serious 
problem; (b) etiology was not defined idiopathic (not defined) 98 (45.6%), hereditary (not 
defined) in 31 (14.4%), alcohol (not defined) 17 (7.9%) and other (not defined) in 69 (32.1%); 
the mean age was 35.7 years with a standard deviation of  13.8 years meaning that the vast 
majority were children or young adults; 159 were female, this is 74% indicating an extremely 
serious problem in understanding exactly what the diagnosis was. 
 
They also now recognise that in hereditary pancreatitis that TPIAT should be largely restricted 
to young adults and children under 21 years of age and only if there are symptoms of severe 
pain (see below). 
 




“The DPSPTP procedure was indicated in only 51 or 6.6%. of the 778 patients with confirmed 
CP in our clinic. We would mainly recommend this procedure in patients with advanced CP 
when all other medical measures to control symptoms have failed [3, 12]. As a special case it 
is also indicated in Hereditary Pancreatitis with PRSS1 mutations from the fifth decade 
onwards when the risk of pancreatic cancer rises dramatically [6]. Total pancreatectomy with 
auto-islet transplantation is not an option for these kinds of patient because there are little or 
no functioning islets in the vast majority [3]. The application of total pancreatectomy with auto-
islet transplantation (TPIAT) should mainly be restricted to children and young adults with 
recurrent acute pancreatitis, especially when associated with PRSS1 mutations, although many 
can be supported well into adult life with medical management [3, 6]. Outside of this indication 
the role of total pancreatectomy with auto-islet transplantation is controversial, as it is now 
recognized that early CP cannot be reliably diagnosed and readily distinguished from chronic 
abdominal pain syndrome with an otherwise normal pancreas [3, 33-35]. This challenging area 
is illustrated by the recent study from the University of Minnesota Medical School, 
Minneapolis, Minnesota with the largest series, in which 215 patients were followed up for at 
least 10 years [36]. In this study  there was no definition of CP or how it was diagnosed; the 
causes although listed were not defined and given as idiopathic (not defined) in 98 (45.6%) 
patients, hereditary (not defined) in 31 (14.4%), alcohol (not defined) in 17 (7.9%) and other 
causes (not defined) in 69 (32.1%) patients [36]. The mean age was 35.7 years with a standard 
deviation of 13.8 years meaning that the majority were children or young adults [36]. Despite 
the relative young population, there were 50 deaths with a 1-year survival rate of 95% and a 
10-year survival of 72%, mainly from unknown causes (58%) and sepsis and/or pneumonia 
(20)%, with death from enterocutaneous fistula, cerebrovascular accident, cancer, kidney 
failure, liver failure, and diabetic complications each contributing 2% whilst sudden death, 
suicide and other causes accounting for the remaining 6% [36]. Moreover 159 of the 215 
patients were female, that is 74%, which casts serious questions as to patient selection and the 
actual underlying diagnosis as gender is not a determinant risk factor for CP [1-4]. In an 
analysis also from Minnesota Medical School restricted to patients with hereditary pancreatitis 
and PRRSS1 mutations, Bellin et al concluded that “age greater than 21 years or disease 
duration longer than 17 years at surgery resulted in insulin dependence after TPIAT, with or 
without partial islet function. When justified by severe pain symptoms, earlier age at surgery 
may improve diabetes outcomes after TPIAT” [37].” 
 
For clarity in the Conclusion in the Abstract and Discussion we refer to using this this operation 
specifically in adults with ned-stage disease: 
 
 
“Duodenum-and spleen-preserving near-total pancreatectomy provided long-term relief in 
adult patients with intractable chronic pancreatitis pain, with improved employment prospects.” 
 
“This study shows that duodenum-and spleen-preserving near-total pancreatectomy can 
provide positive surgical outcomes in adult patients with end stage severe chronic pancreatitis 
including a clinically meaningful reduction in pain and opiate use, and an improvement in 
employment status in nearly two-thirds of patients.” 
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Purpose Total pancreatectomy may improve symptoms in patients with severe end-stage chronic pancreatitis. 
This might be achieved whilst preserving both the duodenum and spleen (DPSPTP). Mature clinical outcomes of 
this approach are presented. 
 
Methods: Single centre prospective cohort study performed between September 1996 and May 2016. 
Demographic, clinical details, pain scores and employment status were prospectively recorded during clinic 
attendance. 
 
Results: 51 patients (33 men, 18 women) with a median (interquartile range) age of 40.8 (35.3-49.4) years, a 
median weight of 69.8 (61.0-81.5) Kg, and a median body mass index of 23.8 (21.5-27.8), underwent intended 
duodenum-and spleen-preserving near-total pancreatectomy for end-stage chronic pancreatitis. Aetiology was 
excess alcohol in 25, idiopathic (no mutation) in 15, idiopathic (SPINK-1/CFTR mutations) in two, hereditary 
(PRSS1 mutation) in seven, and one each post-necrotising pancreatitis and obstructive pancreatic duct divisum in 
1. The main indication for surgery was severe pain. Findings included parenchymal calcification in 79% and 
ductal calculi in 24%, a dilated main pancreatic duct in 57% and a dilated main bile duct in 17%, major vascular 
involvement in  27%, and pancreato-peritoneal fistula in 2%. Post-operative complications occurred in 16 patients 
with one death. Median pain scores were 8 (7-8) preoperatively and 3 (0.25-5.75) at 5 years (p=0.013). Opiate 
analgesic use was significantly reduced post-operatively (p=0.048). Following surgery 22 (63%) of 38 patients of 
working age re-entered employment compared with 12 (33%) working pre-operatively (p=0.016). 
 
Conclusion: Duodenum-and spleen-preserving near-total pancreatectomy provided long-term relief in adult 
patients with intractable chronic pancreatitis pain, with improved employment prospects. 
 
Key words: Chronic pancreatitis; total pancreatectomy; duodenum preserving; spleen preserving; total 
pancreatectomy; surgery; hereditary pancreatitis. 
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Chronic pancreatitis (CP) is a chronic fibro-inflammatory disease of the pancreas, resulting in persistent 
pathological responses to parenchymal injury or stress and pancreatic failure[1]. This has a negative impact on 
quality of life in addition to life-threatening long-term sequelae reducing life expectancy[2, 3]. Incidence ranges 
between 5-14.4 cases per 105 with a prevalence of around 50 per 105, and possibly as high as 120-143 per 105 [3]. 
Aetiological factors include alcohol and tobacco, genetic predisposition, autoimmunity, pancreatic duct 
obstruction and post-necrotising pancreatitis [2-8]. Continuous pancreatic parenchymal inflammation causes 
progressive fibrosis of the pancreas leading to loss of exocrine and endocrine parenchyma, calcification and 
pancreatic duct obstruction, amongst others [3, 9]. Patients can experience steatorrhoea, weight loss, malnutrition, 
gastric acid related symptoms, bloating, vitamin deficiency and osteoporosis due to pancreatic exocrine failure, 
and type 3c diabetes mellitus from endocrine failure[3]. In the long-term there is a 5-25 fold risk of pancreatic 
cancer in sporadic CP rising to 70 fold in hereditary pancreatitis[6, 10].  
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Severe chronic abdominal pain is the most common and distressing symptom[2, 3]. The pathogenesis of pain is 
multifactorial, and the long-term management is extremely challenging[3, 11, 12]. Patients with end-stage CP 
who fail to respond to medical measures, may require surgical intervention[3]. The indications for surgery include 
chronic debilitating pain and complications including biliary and duodenal obstruction, pseudocyst, pancreatic 
ascites, pancreatic fistula, porto-mesenteric venous compression or occlusion, sinistral portal hypertension with 
venous collateralisation and pseudo-aneurysm [3, 11, 13-18]. The surgical options depend on disease extent, 
pancreatic exocrine function and the presence of diabetes. Both drainage and resectional procedures are described, 
however, symptomatic relief following drainage procedures is short lived and various resectional procedures are 
now the current standard of care[3]. Beger’s duodenum preserving pancreatic head resection (DPPHR) is effective 
for head dominant disease, providing decompression of the duodenum, hepatic portal vein, main pancreatic duct 
and intra-pancreatic bile duct[13, 14]. Variants of the Beger operation include the Frey and Berne procedures[15, 
16]. In situations where a classical Kausch-Whipple partial pancreato-duodenectomy and the duodenum-
preserving variants are both possible, the outcomes are similar but the Beger-like procedures can be undertaken 
in more advanced cases[3, 17, 18]. A subset of patients with debilitating symptoms and disease affecting the entire 
pancreas will require a total pancreatectomy, this may be performed with duodenum, pylorus, or splenic 
preservation[3, 19-22]. The Liverpool procedure combines these concepts as a duodenum-preserving and spleen-
preserving near-total pancreatectomy (DPSPTP) [23]. This paper covers our experience with this operation, 
modifications to the technique, and patient outcomes over the last 20 years.  
 
MATERIAL AND METHODS 
 
Study design  
This was a single centre prospective cohort study of 51 symptomatic patients intended to undergo DPSPTP for 
end-stage CP between September 1996 and May 2016 at the Regional Pancreas Unit, Liverpool, UK. The follow-
up censor date was the 31st March 2017. In the original series there were 19 patients between September 1996 and 
November 2002 (none in December) and a further 32 patients from January 2003 and May 2016 [23]. All patients 
with continued follow-up were included in this series. 
 
Indications for DPSPTP  
This operation is only offered to the subset of patients with debilitating end-stage disease affecting the entire 
pancreas with chronic severe abdominal pain unresponsive to optimal medical management. Patients having 
previously undergone partial pancreatectomy with on-going or recurrent symptoms due to progressive disease in 
the remnant pancreas are also considered. Patients without diabetes mellitus meeting the above criteria are 
considered after counselling regarding postoperative diabetes management and complications. All patients must 
demonstrate abstinence from alcohol for more than six months. The procedure is contraindicated if malignancy is 
suspected, but the presence of porto-mesenteric venous thrombosis with varices is only a relative contraindication.  
 
Data collection 
A prospective database recorded demographic, clinical, radiological, genetic and histopathological data along with 
performance status and employment status during initial patient clinical assessment. All patients were asked to 
complete patient reported pain scores on a visual analogue scale (0-10). 
Following discharge, patients were routinely assessed at six weeks, three, six and twelve months, then annually 
with additional review as clinically required. Data collected at follow-up included weight, analgesia requirements, 
employment status and pain scores. To assist in data analysis, analgesia type was subclassified into: parenteral 
strong opiates (e.g. morphine, oxycodone, buprenorphine, fentanyl), enteral strong opiates (e.g. morphine, 
oxycodone), enteral weak opiates (e.g. codeine, tramadol), non-opiates (e.g. paracetamol, NSAIDs), and no 
regular analgesia. Data was censored at the point when patients were discharged, lost to follow-up, or died.  
 
Diagnosis of Chronic Pancreatitis  
The diagnosis of CP was based on clinical and radiological criteria and confirmed in all patients following 
histopathological assessment of operative specimens[3]. The diagnosis of hereditary CP required a germline 
PRSS1 mutation in phase with family history[6]. CP secondary to alcohol required alcohol consumption of 62 
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units per week for 1 year [4]. For the purposes of this study, idiopathic CP included patients with known CFTR 
or SPINK-1 mutations and those with no known cause for CP. Diabetes mellitus was diagnosed according to 
established WHO criteria. The presence of pancreatic exocrine insufficiency was based on clinical assessment 
and the response of steatorrhea to pancreatic enzyme replacement therapy. 
 
Operative description 
The pancreas and duodenum are exposed as described previously [23]. The common hepatic and splenic arteries 
are dissected at the coeliac axis trifurcation and the splenic artery ligated and divided close to this origin. The 
gastro-colic trunk of Henle is ligated and divided, followed by the inferior pancreatoduodenal vein. The pancreas 
is mobilized along its length dividing the superior and inferior peritoneal reflections. The inferior mesenteric vein 
and coronary veins are ligated and divided if arising from the splenic vein. The splenic hilum is dissected and 
transected with a linear stapler leaving the gastrolienal ligament intact, splenic vascular supply is maintained on 
the short gastric vessels. The pancreatic tail is mobilized from the retroperitoneal structures to the confluence of 
the splenic and hepatic portal veins and the splenic vein divided and over sewn 3-4 cm proximal to this confluence.  
 
The pancreatic head is isolated by two rows of circumferential stay sutures, as described by Beger et al[13].  
Near-total pancreatic head resection is performed, preserving a small rim of fibrosed pancreatic tissue on the left 
lateral aspect of the duodenum, between the intrapancreatic bile duct and the duodenum, inferior to the hepatic 
portal and superior mesenteric veins and adjacent to the superior mesenteric artery. It is important to preserve 
either the inferior pancreatoduodenal artery or the superior posterior pancreatoduodenal artery to maintain 
duodenal and distal bile duct vascularization (Figure 1). The bile duct is marsupialized within the bed of the 
pancreatic head by opening this longitudinally and then inserting six or more interrupted 4/0 sutures to 
approximate the edges of the cut bile duct to the adjacent tissues.  The bare pancreatic rim is anastomosed to a 
Roux-en-Y loop. Before 2003, all pancreatic parenchyma was removed to avoid the necessity of constructing a 
Roux-en-Y loop. In our initial series, two cases of bile duct stricture and one case of duodenal stenosis were 
reported relating to local ischemia from this more radical technique[23]. Post-operative complications were 
categorized using the 2009 modification of the Dindo-Clavien classification[24]. 
 
Statistical analysis 
Continuous variables are presented as median and interquartile range (IQR) and analysed using the Wilcoxon 
Rank test for paired data based on a 2-tailed alpha. Categorical variables are presented as frequency and percentage 
and were analyzed using Pearson’s Χ2 test or Fishers exact test. Significance was set at the 5 percent level 




Patients and Preoperative details 
Since 1996, 1,247 patients have been screened with a possible diagnosis of CP. 778 had confirmed CP and gave 
consent to be recruited to the local database. Of these 412 (219 male, 193 female) patients have undergone 
pancreatic surgery. 
 
Fifty-one patients underwent intended DPSPTP for end stage CP (Table I). Five patients with Hereditary 
Pancreatitis (PRSS1 mutation) had a duodenum and spleen preserving total pancreatectomy before 2003 and two 
had a duodenum and spleen preserving near-total pancreatectomy from 2003, none of whom developed pancreatic 
cancer. Two additional patients with a PRSS1 mutation underwent DPSPTP without clinical evidence of CP as 
part of a pancreatic cancer screening program and are not included in this series, although both had good post-
operative long term outcomes. Eight patients required an intra-operative splenectomy for technical (n=6) or 
anatomical (n=2) reasons and two underwent radical total pancreatectomy following the discovery of an 
unexpected cancer and a main duct intraductal papillary mucinous neoplasm respectively. 
 
The most common risk factors for CP were alcohol excess and smoking (Table I). Amongst those consuming 
excess alcohol the median intake was 140 (80-200) units/week for 6 (3-15) years. Amongst the ever smokers the 
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median cigarette consumption was 20 (13.3-28.8) pack-years. Other risk factors are listed in Table I. Fourteen 
patients had undergone previous pancreatic surgery. The predominant symptom was pain in all except one patient. 
This patient had symptomatic painful CP associated with Hereditary Pancreatitis (with a PRSS1 mutation) along 
with parenchymal calcification and both endocrine and exocrine failure, who requested a DPSPTP in his sixth 
decade of life mainly as a prophylactic measure against pancreatic cancer. 
The median preoperative visual analogue pain score was 8 (7-8) out of a maximum score of 10. 90% of patients 
were taking daily opiate-based analgesia (Table I). The median daily oral morphine equivalent dose was 50 (24-
90) mg/day. Thirty-three patients (65%) were diabetic, 31 (61%) insulin dependent and two (4%) controlled with 
oral anti-hypoglycaemics. Forty-four (86%) patients had documented pancreatic exocrine insufficiency with a 
median daily pancreatic lipase dose of 225,000 (150,000-320,000) units. Thirty-one patients were unemployed 
for medical reasons, 15 were employed, three were beyond retirement age and employment status was unknown 
in two patients. Performance status and the American Society of Anesthesiologists grade are listed in Table I. 
 
Pre-operative Radiological Imaging 
The most common radiological findings were parenchymal calcification, main pancreatic duct dilatation and 
pancreatic atrophy (there were missing scans in three patients). Almost a third of patients had vascular 
involvement including porto-mesenteric occlusion or thrombosis and varices (Table II). Examples of radiological 
features are demonstrated in Figure 2. 
 
Operative Outcomes 
All of the patients had CP confirmed histologically. Pancreatic intraepithelial neoplasia (PanIN) was found in five 
patients but no patient had invasive cancer. The median length of stay was 19.5 (11-39.5) days; pre-2003 (n=22) 
this was 25.5 (15.0-44.5) days and post-2003 (n=16) this was 13.5 (10.8-25.0) days (p=0.076); data was missing 
for 3 patients. There was a total of 20 early complications in 16 (39%) patients including one death (Table III). 
Before 2003, there were 15 complications in 11 (47.8%) out of 23 patients and since 2003, there have been 5 
complications in 5 (27.8%) out of 18 patients, demonstrating a trend towards fewer complications post-2003 
technique modification (p=0.192).  
 
Nine (39%) patients were readmitted with late complications pre-2003 of whom eight required a total of twelve 
surgical procedures: adhesiolysis (4) and ileostomy (1) for small bowel obstruction, hepato-jejunostomies (2) and 
hepato-duodenostomy (1) for biliary obstruction, Roux-en-Y revision (1), resection of a large uncinate process 
remnant which had been incomplete removed at the first operation (1), feeding jejunostomy (1) and incisional 
hernia repair (1). From 2003, only six (33%) patients were readmitted with late complications, with two requiring 
further surgical procedures (p=0.142): an ileo-ilial bypass for small bowel obstruction (1) and a hepato-
jejunostomy for a biliary obstruction (1). No patients returned to theatre for splenic complications.  
 
Patient Outcomes 
Patients were followed-up for a median of 3 years, 5 months (1 year - 6 years, 4 months). Post-operative pain 
scores were significantly reduced at 1, 3 and 6 months and 1, 2, 3 and 5 years (Figure 3). Post-operatively 
significantly more patients were opiate free by 3 months (p<0.001) and this remained significant to 5-years 
(p=0.001) (Figure 4).  The daily oral morphine equivalent dose of analgesia required was significantly reduced at 
all post-operative time points (Figure 5). All patients had insulin dependent diabetes post-operatively 
 
Following surgery 22 of 38 patients of working age returned to gainful employment compared to only 12 working 
preoperatively, 13 patients remained unemployed compared with 24 preoperatively (p=0.016); occupation data 
was unavailable pre-operatively for 2 patients and post-operatively for 3 patients.  During the twenty-year study, 
17 patients were lost to follow-up and 12 were discharged. For these 29 patients, the median pain score at last 
follow-up was 2 (0-4) (p<0.001) and the median oral morphine equivalent dose was 0 (0-30) mg/day (p=0.001). 
Only three of these 29 patients represented to clinic, after 3, 7 and 9 years respectively, and only two represented 
with recurrent pain. 
 
DISCUSSION 
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CP remains a challenging disease to manage and chronic abdominal pain is difficult to treat[3, 11, 12]. The primary 
aim of surgery in CP is to provide long-term pain relief and control associated complications, enabling social 
rehabilitation and the opportunity to increase the prospect of gainful employment. The longer-term oral morphine 
equivalent intake remained significantly lower after duodenum preserving total pancreatectomy (with or without 
spleen preservation), although from year to year there was a variance of opiate intake, reflecting the complex 
pathophysiological mechanisms of pain in CP [12].  Longitudinal studies have shown that around 40-75% of 
patients with CP will require surgical intervention at some point during the disease process [25-28]. In our series 
412 (54%) out of 778 patients required surgery. Despite evidence that earlier intervention improves pain outcomes 
and preserves pancreatic function [28] there remains a cohort of patients who present with end-stage disease, 
develop associated complications and fail to respond to other treatment modalities. In this case total 
pancreatectomy remains the only option. Once a patient has developed both endocrine and exocrine failure the 
longer-term improvement in symptoms may outweigh the immediacy of post-operative complications, especially 
in high volume pancreatic centers. Several series have reported immediate postoperative outcomes of total 
pancreatectomy for CP with mortality ranging from 2.9% to 20.6% and complication rates of 15.3% to 51.9% 
(Table IV) [19, 20, 22, 29-31]. In our series there were post-operative complications in 16 (31.4%) patients with 
one (1.96%) death. Compliance with long-term follow up is often a problem with this group of patients and must 
be regarded as a limitation in this as well as other studies. Nevertheless, there were 22 (57.9%) of 38 patients of 
working age who were able to return to gainful work, compared to 28.1% in the one only previously reported 
series of total radical pancreatectomy (with duodenectomy and splenectomy) for chronic pancreatitis [28].  
 
Although duodenum preserving total pancreatectomy has been previously reported [19, 20, 29, 30], and also 
spleen preserving total pancreatomy for chronic pancreatitis [21,29,30], ours is the only series in which these 
procedures are combined. The duodenum-and spleen-preserving near-total pancreatectomy conforms to the 
principle of restricting excisional surgery to the target organ with the intention of optimizing preservation of 
physiological function whilst facilitating the procedure itself. Preserving the duodenum helps reduce nutritional 
compromise and preserving the spleen lessens the risks of sepsis from encapsulated bacterial organisms[14, 
32].The duodenum-and spleen-preserving near-total pancreatectomy compares favorably with these larger 
procedures in terms of post-operative results and, unlike almost all these studies, we report sustained long-term 
benefits.  
 
The key step to this procedure is identification of a readily accessible plane by finger dissection posterior to the 
splenic hilar vessels between the pancreatic tail and the spleen allowing transection with a linear stapler. This 
plane is usually easy to dissect in the absence of severe chronic pancreatitis but more challenging to define with 
end-stage disease affecting the entire distal pancreas. This plane is not previously well described in anatomical or 
surgical textbooks. In the series by Garcea et al. duodenum preservation was attempted in their first six patients. 
They abandoned this technique, after two patients required reoperation for duodenal ischemia [31]. Our operative 
technique was modified post-2003 to preserve a rim of pancreatic tissue on the inner aspect of the duodenum, to 
avoid disruption of the blood supply to the duodenum and distal bile duct.  This was based on the principles of 
duodenum preserving pancreatic head resection introduced by Beger in 1980 [13, 14]. There have been fewer 
post-operative complications in the post-modification cohort and no deaths. None of the patients developed 
malignancy in the rim of pancreatic tissue preserved along the duodenum. Limitations to the current study include 
a relatively small patient cohort that required this special operation.  
 
The DPSPTP procedure was indicated in only 51 or 6.6%. of the 778 patients with confirmed CP in our clinic. 
We would mainly recommend this procedure in patients with advanced CP when all other medical measures to 
control symptoms have failed [3, 12]. As a special case it is also indicated in Hereditary Pancreatitis with PRSS1 
mutations from the fifth decade onwards when the risk of pancreatic cancer rises dramatically [6]. Total 
pancreatectomy with auto-islet transplantation is not an option for these kinds of patient because there are little or 
no functioning islets in the vast majority [3]. The application of total pancreatectomy with auto-islet 
transplantation (TPIAT) should mainly be restricted to children and young adults with recurrent acute pancreatitis, 
especially when associated with PRSS1 mutations, although many can be supported well into adult life with 
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medical management [3, 6]. Outside of this indication the role of total pancreatectomy with auto-islet 
transplantation is controversial, as it is now recognized that early CP cannot be reliably diagnosed and readily 
distinguished from chronic abdominal pain syndrome with an otherwise normal pancreas [3, 33-35]. This 
challenging area is illustrated by the recent study from the University of Minnesota Medical School, Minneapolis, 
Minnesota with the largest series, in which 215 patients were followed up for at least 10 years [36]. In this study  
there was no definition of CP or how it was diagnosed; the causes although listed were not defined and given as 
idiopathic (not defined) in 98 (45.6%) patients, hereditary (not defined) in 31 (14.4%), alcohol (not defined) in 17 
(7.9%) and other causes (not defined) in 69 (32.1%) patients [36]. The mean age was 35.7 years with a standard 
deviation of 13.8 years meaning that the majority were children or young adults [36]. Despite the relative young 
population, there were 50 deaths with a 1-year survival rate of 95% and a 10-year survival of 72%, mainly from 
unknown causes (58%) and sepsis and/or pneumonia (20)%, with death from enterocutaneous fistula, 
cerebrovascular accident, cancer, kidney failure, liver failure, and diabetic complications each contributing 2% 
whilst sudden death, suicide and other causes accounting for the remaining 6% [36]. Moreover 159 of the 215 
patients were female, that is 74%, which casts serious questions as to patient selection and the actual underlying 
diagnosis as gender is not a determinant risk factor for CP [1-4]. In an analysis also from Minnesota Medical 
School restricted to patients with hereditary pancreatitis and PRRSS1 mutations, Bellin et al concluded that “age 
greater than 21 years or disease duration longer than 17 years at surgery resulted in insulin dependence after 
TPIAT, with or without partial islet function. When justified by severe pain symptoms, earlier age at surgery may 
improve diabetes outcomes after TPIAT” [37]. 
CONCLUSION  
 
This study shows that duodenum-and spleen-preserving near-total pancreatectomy can provide positive surgical 
outcomes in adult patients with end stage severe chronic pancreatitis including a clinically meaningful reduction 
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Table I - Demographics of patients listed for DPSPTP 
 
Intended DPSPTP Frequency (Percentage)/Median (IQR) 
Total patients 51 
Male 33 (65%) 
Age, years 40.8 (35.3-49.4) 
Weight, Kg 69.8 (61.0-81.5) 
Body mass index 23.8 (21.3-27.8) 
Symptoms  
Primary symptom severe pain 50 (98%) 
Diabetes 33 (65%) 
Pancreatic Exocrine Insufficiency 44 (86%) 
Risk factors  
Alcohol (>62 units per week for > 1year) 25 (49%) 
Current Smokers 33 (65%) 
Ever Smokers 39 (76%) 
Idiopathic (no mutation) 15 (29%) 
Idiopathic (CFTR/PRSS1) 2 (4%) 
Hereditary CP (PRSS1) 7 (14%) 
Previous Severe Acute Pancreatitis 1 (2%) 
Pancreas divisum 1 (2%) 
Previous Surgery  
Beger’s Procedure 8 (16%) 
Spleen preserving left pancreatectomy 2 (4%) 
Pseudocyst jejunostomy 3 (6%) 
Pancreatectomy necrosectomy 1 (2%) 
Analgesia*  
Parenteral strong opiates 3 (6%) 
Enteral strong opiates 21 (43%) 
Enteral weak opiates 20 (41%) 
Non-opiates 2 (4%) 
No analgesia 3 (6%) 
Performance status  
0 5 (10%) 
1 11 (22%) 
2 9 (18%) 
3 22 (43%) 
4 1 (2%) 
Unknown 3 (6%) 
ASA Grade  
I 4 (8%) 
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Table II – Frequency and percentage of observed radiological features 
 
Radiological Feature Number Assessed  Frequency (percentage) 
Parenchymal calcification 48 38 (79%) 
Dilated main pancreatic duct  46 26 (57%) 
Pancreatic atrophy 48 21 (47%) 
Pseudocyst 47 19 (40%) 
Vascular involvement 44 12 (27%) 
Ductal calculi 45 11 (24%) 
Dilated main bile duct 48 8 (17%) 

















I Surgical site infection (n=1) 
Delayed gastric emptying (n=2) 
Splenic infarction (n=1) 
 Surgical site infection (n=1) 5 
II Abdominal collection (n=1) 
Chest infection (n=1) 
Subclavian vein thrombosis (n=1)  
Abdominal collection (n=2) 
 
5 
IIIa Biliary stricture - stented (n=1) 
Collection/abscess - interventional 
drainage (n=3) 
Biliary stricture- stented (n=1) 
Collection/abscess – 
interventional drainage (n=1) 
6 
IIIb Duodenal stenosis – duodeno-
duodenostomy (n=1) 
 None 1 
Iva Re-laparotomy for bleeding, single 
organ failure (n=1) 
None 1 
IVb Multi-organ Failure (n=1) None 1 
V Multi-organ failure, Death (n=1)  None 1 
Total 15 5 20 
II 37 (73%) 
III 8 (16%) 
IV 2 (4%) 
Employment status  
Unemployed (medical reasons) 31 (61%) 
Employed 15 (29%) 
Retired 3 (6%) 
Unknown 2 (4%) 
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Table IV. Studies since 1980 with 20 or more patients that had a total pancreatectomy for chronic pancreatitis.  
 
*Type of operation: TP = Total pancreatectomy, DpTP = duodenum-preserving TP, SpTP = Spleen-preserving TP, AIT = Auto islet transplantation. **NR=not reported. 
LEGENDS TO FIGURES 
Figure 1. Operative field following duodenum preserving and spleen preserving near-total pancreatectomy. 
Figure 2. Clinical examples of radiological features. 
Figure 2a and b. Female with idiopathic (CFTR mutation) chronic pancreatitis. Extensive parenchymal and ductal calcification is seen throughout the pancreas with significant 
upstream main pancreatic duct dilatation and parenchymal atrophy. Figure 2c. Female with PRSS1 N29I mutation (hereditary pancreatitis). Calcification within the pancreatic 
head and upstream and main pancreatic duct dilatation. Significant disease progression over 12 months with large volume abdomino-pelvic pancreatic ascites from a pancreato-
peritoneal fistula and new gastric and splenic venous collateralisation. 
Figure 3. Post-operative pain scores at each follow-up time period. 
Figure 4. Proportion of patients classified by strongest analgesic group used at each follow-up time period. 
Figure 5. Analgesic use in oral morphine equivalents at each follow-up time period














Weight gain  Post-operative 
employment (% 
of patients) 
Gall et al 28 1981 68 TP **NR 14 (20.6%) NR 57.7% 28.1% 
Cooper 19 1987 83 TP, DpTP NR 4 (4.8%) 83% NR NR 
Flemming 29 1995 40 TP, DpTP, SpTP 15 (37.5%) 2 (5%) 79% NR NR 
Russell 20 1995 52 Tp, DpTP 27 (51.9%) 2 (3.8%) 39% NR NR 
White 21 2000 35 SpTP, TP 10 (28.6%) 1 (2.9%) 82% NR NR 
Garcea 30 2009 85 DpTP, SpTP, TP 
(+/- AIT) 
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